Astellas Pharma (OTCMKTS:ALPMY) was downgraded by analysts at Citigroup Inc. from a "strong-buy" rating to a "hold" rating.
Has Astellas Pharma (TSE:4503) Run Too Far After Its 61% One Year Share Price Jump? [Yahoo! Finance]
VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses [Yahoo! Finance]
VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference